Stockpolly
Search
Delisting risk
ERNA · NASDAQ · Biotechnology

Ernexa Therapeutics (ERNA)

Develops off-the-shelf engineered iMSC therapies for cancer and autoimmune disease.

$4.54
Pre-market+0.04 (+1.00%)
At close$4.50(+3.33%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue001000000000
Gross profit00−1010000000
565533332234
Research & development111111111123
454432111121
Selling & marketing00−1000000000
General & administrative454432111121
Other expenses0000−20000000
Operating income−6−6−6−5−2−3−3−3−2−2−4−4
00−1−1−24−3−5−111−20
Interest income000000000000
Interest expense001123—00000
Other non-operating income000023051−1520
Income before tax−6−6−7−6−27−6−8−3−1−2−6−4
Income tax expense000000000000
Net income from continuing operations−6−6−7−6−27−6−8−3−1−2−6−4
Net income−6−6−7−6−27−6−8−3−1−2−6−4
EPS, basic−$25.75−$28.50−$30.75−$25.50−$123.00−$10.50−$3.75−$15.25−$3.75−$4.75−$6.95−$3.40
EPS, diluted−$25.75−$28.50−$30.75−$25.50−$123.00−$10.50−$3.75−$15.25−$3.75−$4.75−$6.95−$3.40
Weighted average shares, basic000002200011
Weighted average shares, diluted000002200011
EBITDA−5−5−5−4−24−2−8−3−1−7−5−4
Depreciation & amortization101100000000
EBIT−5−6−6−5−25−2−8−3−1−7−6−4